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ABSTRACT 
Macular Edema (ME) is a common complication, leading to severe vision loss in patients with Non-Infectious Uveitis 
(NIU). The treatment of uveitic ME is still very challenging for many ophthalmologists. Various agents, such as 
corticosteroids, anti-vascular endothelial growth factors, and immune-modulators, have been used for combatting 
uveitic ME. However, there is not enough evidence to support the efficacy of any of these agents. Intravitreal 
Dexamethasone Implant (IDI) (Ozurdex; Allergan Inc, Irvine, CA) is a widely administered corticosteroid for the long-term 
management of uveitic ME in certain cases. Ophthalmic implant is made up of a biodegradable copolymer that contains 
glycolic acid and lactic acid. Recent studies have demonstrated that dexamethasone implant effectively improves uveitis-
related ME. The authors suggest that this effect could be sustained for at least six months with close monitoring and re-
treatment, as needed. The current study reviewed major clinical studies about IDI in eyes with NIU and briefly 
overviewed their results. 
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INTRODUCTION
The term uveitis describes a wide range of inflammatory 
conditions, affecting uveal tissue. It is responsible for 5% 
to 20% of blindness in developed countries and 2.8% to 
10% of blindness in the working-age population [1-5]. 
Epidemiological studies have shown that the estimated 
annual incidence and prevalence of uveitis are nearly 17 
to 52/100.000 and 38 to 714/100.000, respectively [6]. 
Macular Edema (ME) and its sequelae may lead to 
persistent visual impairment in patients with 
intermediate or posterior Non-Infectious Uveitis (NIU). 
Its prevalence varies between 20% and 30%, occurring in 
up to 50% of uveitis cases in some clinical trials [7, 8]. 
The pathophysiological mechanism of ME has not been 
fully elucidated in uveitis. The breakdown of inner and/or 
outer blood-retina barrier and/or disturbance in the 
pumping function of the retinal pigment epithelium is 
considered as the main mechanism. Constant release of 
numerous chemical mediators, such as various cytokines 
(interleukins, tumor necrosis factor α, etc.), leukotrienes, 
prostaglandins, nitric oxide, vascular endothelial growth 
factor, and protein kinase C causes increased retinal 
vascular permeability that leads to extravasations of the 
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fluid, proteins, and other macromolecules to the retinal 
interstitium, which is particularly pronounced at the 
macula and it may accumulate in cystoid spaces by 
expanding the extracellular compartments [6, 9-15]. The 
cystoid spaces were mainly located in the outer retinal 
layer, and more precisely in the Henle layer [15]. Optical 
Coherence Tomography (OCT) has provided new insights 
in the morphological changes occurring in patients with 
uveitic ME and is widely used in the diagnosis and follow-
up of these patients. It is also useful for detecting early 
ME and the evaluation of response to treatment, even in 
the presence of severe vitreous haze. Diffuse Macular 
Edema (DME), Cystoid Macular Edema (CME), and Serous 
Retinal Detachment (SRD) have been reported as three 
different OCT patterns of fluid accumulation in uveitic 
patients [16]. In a study conducted by lanetti et al. [17], 
the percentages of CME, DME, and SRD were reported as 
58%, 42%, and 28%, respectively. 
Treatment of NIU is still very challenging. Steroids have 
long been used effectively in the control of uveitic 
inflammation together with other immunosuppressants 
and/or biological agents. The main immunosuppressive 
effect of steroids occurs by reducing neutrophil 
transmigration, cytokine production, and vascular 
endothelial growth factor production, induced by pro-
inflammatory cytokines [18]. It can be administered 
systemically, topically, and locally [intravitreal and 
periocular (subconjunctival, orbital floor, and sub-
Tenon)] [19]. However, the most effective route of 
steroid administration is still a matter of debate. Topical 
steroids cannot control inflammation in intermediate and 
posterior uveitis, since effective vitreous concentrations 
cannot be achieved [20]. Although systemic steroids are 
effective in controlling intraocular inflammation and its 
complications, prolonged usage may result in undesirable 
systemic (cushingoid habitus, weight gain, systemic 
hypertension, steroid-induced diabetes, osteoporosis, 
necrosis of the hip, gastrointestinal disturbance, 
electrolyte imbalance, psychosis, and insomnia) and/or 
ocular [cataract formation and Increased Intraocular 
Pressure (IOP)] side effects [20-23]. Local routes have 
been used to avoid the systemic side effects of steroids 
and to achieve effective local tissue concentrations. In 
periocular steroid injections, short-term and uncertain 
therapeutic drug concentrations are obtained in the 
vitreous cavity. It may also cause serious ocular 
complications, such as optic nerve injury, extraocular 
muscle injury, globe rupture, retinal and/or choroidal 
vascular occlusion, ptosis, subdermal fat atrophy, and 
hypopigmentation of periocular skin [24, 25]. Therefore, 
intravitreal injections have become an accepted 
approach to transfer therapeutic agents directly to the 
choroid and retina. Intravitreal triamcinolone acetonide 
is still used as an off-label treatment modality in NIU. 
However, short intraocular half-life, local side effects, 
such as increase in IOP and development of cataract, 
usually restricts its use. In the recent years, sustained 
corticosteroid-release implants have been developed and 
legally approved for injection in the vitreous cavity. 
Intravitreal Dexamethasone Implant (IDI) (Ozurdex; 
Allergan Inc, Irvine, CA) is one of the sustained-release 
implants approved by the US Food and Drug 
Administration for treating posterior NIU [21, 24]. It 
consists of a biodegradable copolymer of glycolic acid 
and lactic acid that erodes to carbon dioxide and water, 
while 700 micrograms (µg) of dexamethasone is 
gradually released in the eye [26-29]. The 
pharmacokinetic features of the implant are responsible 
for the response pattern. The drug release peaks at two 
months and then a steady decline occurs that prolongs 
its effect up to six months [29].
 
The action mechanism of 
the dexamethasone is the same as other steroids. It acts 
by binding to the steroid receptors in the cytoplasm, and 
then modifying the DNA expression in the cell nucleus. 
Clinical Trials of Dexamethasone Implant for Non-
Infectious Uveitic Macular Edema 
The major clinical studies examining the effect of IDI on 
ME in patients with NIU are summarized in Table 1 [21, 
24, 30, 31]. 
HURON (dexamethasone intravitreal implant for non-
infectious intermediate or posterior uveitis) was the first 
prospective randomized sham-controlled trial 
investigating the efficacy of IDI in patients with 
intermediate or posterior NIU [24]. In this 26-week study, 
a significant reduction in Central Macular Thickness 
(CMT) was detected at week eight and 26 after the first 
IDI injection. The mean decrease in CMT from baseline 
was -99 µm at week eight and -50 µm at week 26. The 
authors suggested that the significant improvement in 
CMT was maintained for six months [24]. 
Cardoso et al. (30) reported the outcomes of 41 eyes of 
31 patients with posterior NIU, treated with IDI. They 
classified the ME as CME (26 eyes), CME with Sub-Retinal 
Fluid (SRF) (nine eyes), DME (four eyes), and isolated SRF 
(two eyes). In this study, one month after the IDI, 
significant reduction in CMT was observed in most 
patients. However, CMT showed a deterioration in up to 
70% of patients six months after the injection, and 13 
eyes required repeat injections. The average time to 
relapse was 6.7 months (Range, 2 to 15) and overall 
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Table 1: The Summary of Studies on Non-infectious Uveitic Macular Edema Treatment with İntravitreal Dexamethasone İmplant 
Study design, sample size 
and mean or median 
follow-up after the first 
injection 
Type of uveitis Number of implant Changes in central macular thickness 
during the follow-up period 
Pohlmann et al. [32], (2018) 
*Prospective study - 
*0.70 mg IDI (n:109 eyes) 
- *22 months (6-44 
months) 
Intermediate (50%, n:54), 
posterior (42%, n:46) and 
panuveitis (8%, n:9) 
*Single implant n:31 eyes (28%) - 
*Multiple implantations n:78 eyes 
(72%). 2 implants (78 eyes) 3 
implants (48 eyes) 4 implants (31 
eyes) 5 implants (17 eyes) 6 
implants (12 eyes) 7 implants (3 
eyes) 
*Significant decrease in CMT at 1, 3 
and 6 months after first injection - 465 
± 142 μm (at baseline) - 318 ± 80 μm 
(at 1 month) - 342 ± 92 μm (at 3 
months) - 388 ± 106 μm (at 6 months) 
Yalcınbayır et al. [33], (2018) 
*Retrospective study  - 
*0.70 mg IDI (n:27 eyes) - 
*24 months 
Posterior uveitis (Behçet 
disease) 
*Single implant n:22 eyes (81%) - 
*Multiple implantations n:5 eyes 
(19%). 2 implants (5 eyes) 
*Significant decrease in CMT at 
1,3,and 6 months - 406 ± 190 μm (at 
baseline) - 243 ± 101 μm (at 6 months) 
Lowder et al. [24], (HURON Study Group) (2011) 
*Prospective study - 
*0.70 mg IDI (n:77 eyes) - 
*26 weeks 
Intermediate (82%, n:63) 
and posterior uveitis 
(18%, n:14) 
*Single implant *Significant reduce in CMT at weeks 8 
and 26. 
Cardoso et al. [30], (2017) 
*Retrospective study - 
*0.70 mg IDI (n:41 eyes) - 
*13.4 months (2-23 
months) 
Anterior, intermediate 
and posterior uveitis 
*Single implant n:28 eyes (68.3%) - 
*Multiple implantations n:13 eyes 
(31.7%). 2 implants (10 eyes) 3 
implants (2 eyes) 4 implants (1 eye) 
*Significant reduce in CMT at 1 and 3 
months - 461 ± 158 μm (at baseline) - 
308 ± 93   μm (at 1 month) - 340 ± 110 
μm (at 3 months) - 442 ± 172 μm (at 6 
months) - 361 ± 108 μm (at 12 months) 
Tsang et al. [34], (2017) 
*Retrospective study - 
*0.70 mg IDI (n:25 eyes) - 
*270 days  (101–582 
days) 
Anterior, intermediate 
and posterior uveitis 
*Single implant n:18 eyes (72%) - 
*Multiple implantations n:7 eyes 
(28%). 2 implants (4 eyes) 3 
implants (3 eyes) 
*Significant reduction in CMT in 91% of 
eyes at 3 months. - 590 ± 28 μm at 
baseline - 380 ± 28 μm at 1 month - 
370 ± 31 μm at 3 months - *The 
median time to recurrence after 
injection 6 months. 
Khurana et al. [35], (2015) 
*Retrospective Study - 
*0.70 mg IDI (n:18 eyes) - 
*12  months 
Intermediate uveitis (39%, 
n:7) Birdshot 
chorioretinitis (22%, n:4) 
Sarcoidosis (22%, n:4) 
Other (17%, n:3) 
*Single implant n:8 eyes (44%) - 
*Multiple implantations (range from 
1 to 4) n:10 eyes (56%) 
*Complete resolution of CME 89% of 
eyes at 1 month. 72% of eyes at 3 
months. * The rate of eyes with no 
recurrence of CME  35% at 6 
months.  30% at 12 months. - *The 
median time to recurrence of CME 
201 days. - *Reccurence time of CME 
was shorter in eyes with epiretinal 
membrane present at baseline (110 
days). 
Sella et al. [21], (2015) 
*Retrospective Study - 




*Single implant n:9 eyes (64.3%) - 
*Multiple implantations n:5 eyes 
(35.7%) 3 implants (5 eyes) 
*Significant reduction in CMT at 1 
month and 3 months, then increased 
at 3-6 months. 
 
Bansal et al. [36], (2015) 
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Study design, sample size 
and mean or median 
follow-up after the first 
injection 
Type of uveitis Number of implant Changes in central macular thickness 
during the follow-up period 
*Prospective study - 
*0.70 mg IDI (n:30 eyes) - 
*6 months 
Anterior, intermediate 
and posterior uveitis 
*Single implant n:27 eyes (90%) - 
*Multiple implantations n: 3 eyes 
(10%) 2 implants (3 eyes) 
Significant reduction in CMT at week 4, 
maintained during the follow-up visits 
up to week 24. - 524  ± 88 μm (at 
baseline). - 269  ± 41 μm (at 4 weeks) - 
274  ± 83 μm (at 12 weeks) - 289  ± 73 
μm (at 24 weeks) 
Pleyer et al. [37], (2014) 
*Prospective study - 
*0.70 mg IDI (n:84 eyes) - 
*6 months 
Intermediate (51%, n:43) 
and posterior uveitis 
(49%, n:41). 
*Single implant *Significant decrease in CMT at week 
4. The effect sustained till at week 24. - 
463  ± 164 μm (at baseline) - 299  ± 




*Retrospective study - 
*0.70 mg IDI (n:27 eyes) - 
*14 months (8-27 
months) 
Anterior, intermediate 
and posterior uveitis 
*Single implant n:4 eyes (15%) - 
*Multiple implantations n: 23 eyes 
(85%) 2 implants (7 eyes) ≥3 
implants (16 eyes) 
*Significant decrease in CMT at week 
4, maintained at 3 months. - 478 ± 330 
μm (at baseline) - 278 ± 206 μm (at 
week 4) 
Ventura et al. [39], (2014) 
*Retrospective study - 
*0.70 mg IDI (n:82 eyes) - 
*12 months 
Intermediate uveitis 
(37.8%, n:31), posterior 
uveitis (23.1%, n:19), and 
panuveitis (21.9%, n:18) 
*Single implant n:43 eyes (52.4%) - 
*Multiple implantations n:39 eyes 
(47.6%). 2 implants (24 eyes) ≥3 
implants (15 eyes) 
*Reduced in CMT peaked at week 4, 
but slightly deteriorated till 12 months. 
- 469 ± 193 μm (at baseline) - 267 ± 74 
μm (at 1 month) - 366 ± 140 μm (at 6 
months) - 355 ± 160 μm (at 12 months) 
Adán et al. [31], (2013) 
*Retrospective study - 
*0.70 mg IDI (n:17 eyes) - 
*9.6 months (6-17 
months) 
Anterior, intermediate, 
posterior uveitis and 
panuveitis. 
*Single implant - n:9 eyes (53%) - 
*Multiple implantationsn:8 eyes 
(47%) 2 implants (8 eyes) 
Significant reduction in CMT at week 4. 
The effect maintained at 3 months, but 
slightly deteriorated till 6 months. - 
461 ± 121 μm (at baseline) - 277 ± 66 
μm (at week 4) - 349 ± 143 μm (at 3 
months) - 394 ± 138 μm (at 6 months) 
 Abbrevations: IDI: Intravitreal Dexamethasone Implant; CMT: Central Macular Thickness; mg: Milligram; μm: Micrometer; n: Number. 
In a very recent study conducted by Pohlmann et al. [32], 
the outcome of 109 eyes of 76 patients with NIU, who 
underwent IDI (a total of 298 implants) was analyzed, 
prospectively. More than three dexamethasone implants 
were injected in 44% of eyes. The CMT decreased 
significantly from 465 µm at baseline to 318, 342, and 
388 µm after one, three, and six months, respectively. 
Similar trends were seen in eyes receiving a second, 
third, and fourth dexamethasone implant. The mean 
time of injection between the first to second, second to 
third, and third to fourth IDI was reported as 10.3, 8.6, 
and 9.2 months, respectively. This research reported that 
CMT decreased markedly at one, three, and six months 
after the first three IDI. The authors concluded that 
reduction in CMT, obtained with the first injection, could 
also be achieved in repeated injections. In this study, the 
authors noted that the greatest overall benefit was 
achieved in patients with no systemic treatment and 
patients receiving antimetabolites and cyclosporine A. 
In a recent study, Yalcinbayir et al. [33] reported on the 
results of IDI in uveitic ME, secondary to Behçet's Disease 
(BD). The authors examined 27 eyes of 20 patients with 
BD, who received IDI for CME. They reported that CMT 
was markedly reduced from baseline values at one, 
three, and six months after the injection. The authors 
stated that a second implant was required in five eyes 
within an average of 16 months. The overall number of 
injections per eye was 1.18. As a consequence of the 
current study, the authors suggested that IDI was 
efficacious in reducing ME in Behçet uveitis. 
Although NIU less commonly occurs in children, it is an 
important cause of severe visual loss. Periocular 
corticosteroids, systemic corticosteroids, other systemic 
antimetabolites and/or biologic agents are often used for 
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controlling intraocular inflammation. Long-term steroid 
usage in the pediatric cases causes significant side 
effects, such as growth retardation, osteoporosis, and 
other physiological disorders. Therefore, IDI has been 
used for controlling longer duration of local inflammation 
in these patients [21].
 
The use of IDI in the pediatric age 
group has been limited and a few studies have been 
conducted on the efficacy of the implant.
 
Sella et al. [21] 
investigated 14 eyes of 10 patients aged 6.5 to 15 years 
old with intermediate and posterior NIU, who were poor 
responders to standard uveitis treatment. They reported 
that CME was present in ten eyes. The authors 
demonstrated a decrease in CMT (10 eyes; 100%) 
between one week and three months after the first 
injection, followed by a fading treatment effect within 
three to six months. In this study, five eyes needed 
repeated injections due to reccurence in ME. The 
average interval time between two injections was found 
to be 4.8 months (range, four to six). The authors 
emphasized that the response pattern after the repeated 
injections was similar to that of the first injection. 
Some authors performed pars plana vitrectomy in eyes 
with resistant uveitic ME [40-42]. Intravitreal drugs in 
vitrectomized eyes may have a short half-life due to 
increased drug clearance [41]. In a study comparing the 
efficacy of IDI on uveitic ME between vitrectomized and 
non-vitrectomized eyes, the authors showed similar 
efficacy in terms of reduction in CMT in both groups.  
 
 
Figure 1: Color Fundus and Optical Coherence Tomographic (OCT) 
Images of the Left Eye of a Patient with Behçet’s Disease under 
Systemic Azathioprine and Cyclosporin Treatment yet still 
Experiencing a Severe Unilateral Uveitis Attack. Fundus Image of the 
Left Eye prior to Dexamethasone Implant Administration showing 
Severe Vitreous Haze (A). OCT could not be Obtained Sufficiently due 
to Severe Vitritis at the Time (B). Six Weeks after Receiving 
Intravitreal Dexamethasone Implant, Vitreous Haze was Resolved, 
Dramatically (C), and Left Macula was Normal, Tomographically (D). 
 
Figure 2: Fundus Auto-fluorescence Image obtained from the Left Eye 
of a Patient with Unilateral Intermediate Uveitis, who did not Receive 
any Local or Systemic Medical Treatment Depicting 
Hyperautofluorescence Petaloid Pattern at the Fovea (A). Late Venous 
Phase of Fluorescein Angiographic Image showing a Typical Petaloid 
Pattern of Macular Leakage together with Perifoveal Retinal Leakage 
and late Staining of the Optic Disc (B). Baseline Optical Coherence 
Tomography (OCT) showed Cystoid Macular Edema and a Serous 
Macular Detachment (C). Six Weeks after receiving the Intravitreal 
Dexamethasone Implant, OCT Image delineated an almost Total 
Improvement in Macular Edema and Separation of the Posterior 
Hyaloid Membrane following the Injection (Red Arrows) (D). 
 
They stated that this reduction was maintained during 
the entire follow-up period. The authors emphasized that 
there was no significant difference between the two 
groups in terms of the number of injections and the time 
interval among the injections. They suggested that the 
median interval between the two injections in both 
groups was five months [42]. Likewise, in a study 
conducted by Adán et al. [31], the efficacy of IDI on 
uveitic ME in vitrectomized eyes was similar to that of 
non-vitrectomized eyes. Two of the clinical cases treated 
with IDI are displayed in Figure 1 and 2. 
CONCLUSIONS 
Intravitreal Dexamethasone Implant has already found a 
niche in the treatment armamentarium of uveitic ME, as 
several papers have demonstrated its undeniable 
positive effect on uveitic ME. Dexamethasone implant 
can either be used as a single therapeutic agent in some 
selected cases or as an adjunct agent to an already 
ongoing systemic therapy or as a bridging treatment 
option while changing the systemic agents. 
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